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Background: Projections about when research milestones will be attained are often of interest to 
patients and can help inform decisions about research funding and health system planning.   
 
Objective: To collect aggregated expert forecasts on the attainment of 11 major research 
milestones in Parkinson’s disease (PD). 
 
Methods: Experts were asked to provide predictions about the attainment of 11 milestones in PD 
research in an online survey.  PD experts were identified from: 1) The Michael J. Fox 
Foundation for Parkinson’s Research data base, 2) doctors specializing in PD at the ranked 
neurology centers in the US and Canada, and 3) corresponding authors of articles on PD in top 
medical journals. Judgments were aggregated using coherence weighting.  We tested the 
relationship between demographic variables and individual judgments using a linear regression. 
 
Results: 249 PD experts completed the survey.  In the aggregate, experts believed that new 
treatments like gene therapy for monogenic PD, immunotherapy and cell therapy had 56.1%, 
59.7%, and 66.6% probability, respectively of progressing in the clinical approval process within 
the next 10 years.  Milestones involving existing management approaches, like the approval of a 
deep brain stimulation device or a body worn sensor had 78.4% and 82.2% probability of 
occurring within the next 10 years.  Demographic factors were unable to explain deviations from 
the aggregate forecast (R2=0.029). 
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Conclusions: Aggregated expert opinion suggests that milestones for the advancement of new 
treatment options for PD are still many years away. However, other improvements in PD 





Parkinson’s disease (PD) research and development is progressing along many fronts, including 
precision medicine, experimental new therapies, and body worn sensors for diagnosis and 
monitoring. Though major advances in disease modifying therapy have yet to arrive, novel 
therapeutic strategies like deep brain stimulation or better levodopa infusion have improved the 
symptomatic management of PD.  
 
Because PD has a protracted course, patients and physicians are often keenly interested in expert 
impressions of existing research, which can help estimate when new treatments and management 
strategies are expected to emerge and be trialed. Realistic projections of the attainment of major 
research milestones can help physicians and patients calibrate their expectations. They can also 
help with research and health system planning. For example, knowing when novel interventions 
are likely to mature can help healthcare systems determine when to build capacity for their 
deployment. Knowing which therapeutic strategies are likely to mature first can help funding 
bodies set priorities or issue calls that are relevant to that milestone. 
 
Forecasting scientific breakthroughs is often not amenable to computational approaches, in part 
due to the diversity of variables that drive scientific progress.[1]   In what follows, we used a 
“wisdom of the crowd” approach for aggregating expert forecasts about the timing of eleven 
major research milestones for the future management and diagnosis of PD. Such approaches 
have been shown to offer greater predictive accuracy than individual judgments by reducing the 
effect of random variation between expert judgments, while pooling the judgments of individuals 
who have widely varying knowledge.[2–4]  Previously, wisdom of crowds approaches have been 
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used in medicine to improve predictive accuracy in areas like prognosis[5], diagnosis[4,6], and 
emergence of diseases.[7–9]  Our approach used a method known as coherence weighting, where 
the aggregation of forecasts is weighted based on the extent to which the forecasts are 
probabilistically coherent.  This approach has demonstrated effectiveness in improving the 
accuracy of lay forecasts in other domains, where those who provided more coherent forecasts 




PD experts were recruited from two sources: 1) the Michael J. Fox Foundation for Parkinson’s 
Research database and 2) an independent sample constructed by identifying doctors specializing 
in PD at the 25 top ranked  neurology departments in the US (as rated by US News and World 
Report), the top 3 largest hospital systems in Canada, and by identifying corresponding authors 
of articles on PD from the last 5 years in BMJ, Lancet, PLoS Med, NEJM, JAMA, Annals of 
Neurology, JAMA Neurology, Lancet Neurology, Neurology and Movement Disorders.  Experts 
were solicited for survey participation three times. 
 
Our survey sought forecasts for 11 major milestones in PD research (this was the largest number 
of forecast queries that could fit in a 30-minute survey). Milestones were generated by our three 
co-authors with PD expertise (RB, AL, TS) based on their perceptions of what would constitute a 
significant improvement on the current state of the field.  We then helped select milestones that 
were objectively verifiable, diverse, and thought to be of interest to the patient community.  
Briefly, each PD expert co-author generated 10-15 potential milestones, and then rated the 
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milestones created by the other co-authors on their importance and verifiability.  We selected the 
highest rated milestones while ensuring that some selected milestones were likely to occur earlier 
while others were likely to occur later and covered a range of event types including FDA 
approval and trial launch. Particular milestone events for new treatments (e.g. FDA approval vs. 
launch of a trial vs. clinical practice guideline recommendations) were selected in order to enable 
capture of near term as well as late-occurring advances. The survey was created on Qualtrics.  
Experts provided the probability of milestone attainment in three time bins spanning the next 10 
years (within the next 2 years, within the next 2-6 years and within the next 6-10 years), and 
separately the probability of milestone nonattainment within 10 years. In order to assess 
probabilistic coherence for the purpose of coherence weighting, we allowed experts to enter 
probabilities that did not sum to 100% across time bins.  A graphical depiction of our survey 
process is provided in Figure 1. Milestone questions are provided in Table 1. Milestones were 
presented in random order. 
 
Our survey contained five additional components. First, for milestones entailing launch or 
completion of a trial, we asked experts to predict the probability the trial would be positive on its 
primary endpoint. Second, we collected forecasts of whether there would be an FDA approval 
within the next 10 years for therapies in the following areas: gene therapy, repurposed small 
molecule therapy, novel small molecule therapy, stem cell therapy or a therapy not falling within 
the preceding categories.  Note that, unlike the 11 milestone questions, these questions were not 
worded with sufficient precision to enable forecast verification. We additionally asked 
participants to rate their familiarity with gene therapy, precision medicine, alpha-synuclein 
targeted treatment and deep brain stimulation on a seven point Likert scale from extremely 
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unfamiliar to extremely familiar.  Third, we asked participants to rate the same four kinds of 
treatments on their clinical promise on a nine point Likert scale from minimal promise to 
maximal promise.  None of the above questions were asked using a coherence weighting format. 
Last, we collected the following demographic items from experts: sex, age, education and 
number of clinical trials participated in. H-indices of all participants were obtained using Scopus. 
 
Our survey received approval by McGill IRB; experts provided consent online. 
 
Aggregated forecasts were produced in two stages.  First, the raw forecasts were all made 
coherent by ensuring that the forecasts for each time bin jointly summed to 100%.  We did this 
by taking each set of incoherent forecasts, and finding the coherence set of forecasts that was 
closest to them as measured by the Euclidean distance.  For example, if someone provided 
forecasts of 30%, 40%, 40%, 30% for the four time bins their forecasts would be incoherent, 
because they sum to more than 100% percent.  These forecasts would be coherentized by finding 
the closest set of coherent forecasts, in this case 20%, 30%, 30%, 20%.   Once the forecasts were 
coherentized, we averaged them together to produce an aggregate forecast.  This average was 
weighted by how incoherent each forecast was originally, that is how far from 100% the sum 
was, with lower weight given to more incoherent forecasts.[10]  Post-hoc, we tested whether the 
forecasts for North American experts were different from the forecasts for non-North American 
experts for the two milestones dealing with FDA approvals using a Kolmogorov-Smirnov test for 
equality of distributions. 
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As an exploratory analysis we tested for differences in the deviation of forecasts from the 
coherence weighted mean as a function of the demographic characteristics of experts.  Under the 
assumption that the coherence weighted mean is the best obtainable prediction for each 
milestone, this dependent variable serves as a proxy for forecast accuracy.  To simplify the 
analysis, we first dichotomized forecasts by summing each individual’s forecasts for each 
milestone for the first three time bins to create a forecast of the probability of the milestone 
occurring in the next 10 years.  We performed a similar dichotomization for the coherence 
weighted means, and then took the absolute value of their difference.    We subjected this 
dependent variable to a linear regression on age, H-index, number of clinical trials participated 
in, an indicator variable for gender, a set of indicator variables for degrees held and incoherence, 
along with milestone controls.  Based on a preliminary exploration of the data, we also 
developed a model where we used a log transformation on H-index and number of trials 
participated in to deal with some of the skew in these variables.  When we compared models we 
found that the fit was not notably different (R2=0.029 versus R2=0.029), so we report the results 
for the untransformed model only.  
 
Data Availability Statement: CSV files containing both raw and coherentized forecasts as well 




Characteristics of Expert Participants 
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249 experts in PD completed our survey; 87 were recruited through the MJFF database (of 2092 
contacted) while 162 were recruited from our independent sample (of 811 contacted).  Median 
age of respondents was 48 (range 24-86); 31% of respondents were female; degrees held by our 
respondents were MD (24%), MD/PhD (27%) PhD (36%), and Master or less (13%); median H-
index of respondents was 22.5 (standard deviation 24.27, range 1-192).  Median H-index of the 
population from which our independent sample was drawn was 25 (standard deviation 26.95, 
range 1-194).  A Kolmogorov-Smirnov test for equality of distributions did not reject the null 
hypothesis that our sample and the population had the same distribution of H-indices  (D=0.81, 
p=0.21). Experts were located in North America (46%, with 35% total from the USA), Europe 
(35%), Asia (7%), Oceania (3%), and Africa and South America (1% each).  We were unable to 
obtain location information for 5% of our respondents.  
 
Forecasts on Milestone Attainment 
The median incoherence was 14.5%, (26.4% standard deviation, range 0%-127%), meaning that 
forecasts of half of experts summed to either less than 85.5% or more than 114.5%.  Forecasts 
about the timing for milestone attainment are depicted in Figure 2 (the distribution of individual 
forecasts for each milestone can be found in the Supplementary materials). Three of the four 
milestones judged to be least likely to be attained in the next 10 years concerned disease 
modifying therapies, while those judged most likely to occur are largely refinements in existing 
therapies. The aggregated predictions of experts for trials being positive on their primary 
endpoint was 44.5% for the trial specifying eligibility based on GBA mutational status trial 
(Precision Medicine Therapy), 39.4% for the pluripotent stem cell trial (Cell Therapy), 47.0% for 
the trial integrating an alpha synuclein imaging agent (Imaging), and 40.5% for the non-
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cholinesterase inhibiting drug trial (Treatment for PD-MCI).  Table 2 contains the mean and 
standard deviation for each time bin for the FDA related milestones for North American and 
non-North American experts, as well as the results of a Kolmogorov-Smirnov test for equality of 
distribution comparing the distributions of predictions.  None of the tests were significant 
indicating there was no difference in the distribution of these predictions between North 
American and non-North American samples. 
 
Judgments on Treatment Categories and Clinical Promise 
The mean prediction for FDA approval in the next 10 years for the different treatment categories 
are displayed in Table 3. The mean familiarity and clinical promise ratings with different 
treatment categories are displayed in Table 4.  
 
Relationship Between Expert Characteristics and Forecasts 
For our exploratory analysis, we evaluated 2348 forecasts out of 2733 available forecasts (for 6 
experts, we were missing all demographic information; for another, 35 we were missing data on 
one or more covariates in the regression model).  The model accounted for very little of the 
variation in the data (R2=0.029). The coefficients are listed in Table 5.  The coefficients on age, 
clinical trials participated in and H-index were not significantly different from zero (t=-0.09, 
p=0.93; t=-0.76, p=0.45; t=0.27, p=0.79).  The factor describing education significantly 
improved model fit (F(3, 2348)=2.85, p=0.04); those with MDs, MD-PhDs and PhDs all 
provided predictions that were further from the coherence weighted mean than those with only a 
Masters degree.  The factor describing gender also significantly improved model fit (F(2, 
2348)=3.84, p=0.02), with male participants providing predictions further from the coherence 
 12 
weighted mean than female participants.  Overall, this regression analysis suggests that there is a 
great deal of unexplained variation in the data, and the only variables with any predictive power 




We synthesized a large and diverse sample of expert opinions about the timing of attainment of 
major research milestones in PD. With the exception of precision medicine approaches, experts 
believed that advances in new treatment modalities are likely still some years away, viewing 
breakthroughs in disease modifying treatments as having a 30-40% chance of not occurring at all 
within ten years. Experts were most pessimistic about FDA approval of Parkinson’s monogenic 
gene therapy relative to other disease modifying therapies, though this may have more to do with 
the milestone referring to an FDA approval as opposed to a clinical trial. When asked about 
broad treatment categories rather than more specific milestones, experts rated the probability of 
the FDA approving a new treatment within 10 years as less than 50% for all categories.  Doubts 
about near term breakthroughs in disease modification were echoed by forecasts that primary 
endpoints in trials are more likely to be non-positive than positive, and the fact that experts 
generally predicted a less than 50% probability of an FDA approval of a new PD therapy across 
five different treatment platforms.  However, on average experts rated the clinical promise of all 
treatment categories we asked about as above the mid point of our scale, indicating that they 
believe these lines of research are worth pursuing even though they are less likely to produce 
concrete gains in the next 10 years.  
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Experts did, however, believe improvements for existing therapy and improvements in 
diagnostic techniques are likely in the near future.  For example, experts predicted a 2 in 3 
chance that a repositioned drug will demonstrate disease-modifying activity in patients within ten 
years. Experts anticipated that clinical practice guidelines are more likely than not to endorse the 
use of body worn sensors for PD diagnosis within the next six years. 
 
Our regression analysis of the relationship between expert characteristics and forecasts suggest 
that simple demographic characteristics shed very little light on “accuracy”.  The only significant 
contributions to model fit were that those individuals with a Master’s degree or less tended to 
make predictions closest to the coherence weighted mean, and that men tended to make 
predictions further from the coherence weighted mean than women. However, both effects were 
small.  If the coherence weighted mean is in fact an accurate assessment of the true probabilities, 
this analysis implies that looking at demographic variables, even those that supposedly track 
expertise, may not be the optimal experts with the best predictive abilities.   This would suggest 
that when decisions like funding or priority setting hinge on assessing the timing of scientific 
advances, granting agencies or policy-makers may be better off randomly recruiting advisors 
from a list of established experts rather than seeking out rarefied (and often expensive) expertise. 
  
Our study has limitations. The first concerns milestone sampling.  The wording of our survey 
questions was very specific and may not have captured the promise of broader milestone 
categories. For example, our gene therapy milestone excluded non-viral vector therapies like 
anti-sense oligonucleotides, and only concerned treatments for monogenic PD. As such, answers 
to this question should not be viewed as proxies for all gene therapy approaches being tested. 
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The use of specific milestone questions reflected the scientific imperative in forecast research of 
ensuring that each question is clear, unambiguous, and verifiable. The inclusion of more general 
questions might mitigate this limitation. Related to this, many milestone questions concerned 
outcomes in the U.S. drug approval process. As a consequence, forecasts reflected beliefs about 
both clinical promise and the pacing and standards used for the approval process itself.  To the 
latter point, non-North American based experts may have found the task of forecasting 
regulatory attainment milestones more difficult, though their forecasts on the FDA related 
milestones appear similar overall to the those given by the North American based experts.   The 
second set of limitations concern our expert sampling.  Despite coherence weighting and 
selective eligibility criteria, forecasts could have been affected by response bias. Even so, our 
sample was largely composed of experts who had records of research productivity and who were 
affiliated with top neurology programs. Our demographic analysis of nonresponders did not 
suggest striking biases in our sample. The third set of limitations concern the predictions 
themselves. It remains to be seen whether the wisdom of the crowd approach we used will 
provide an accurate assessment of timelines. Further, the very availability of predictions reported 
in our study could change the probability of milestones being achieved.  A last set of limitations 
concerns secondary analyses. A more comprehensive collection of demographic and cognitive 
features of experts might reveal other important factors that relate to forecast skill.  Also, this 
analysis was conducted after the data had been analyzed for our primary objectives; all p-values 
should be understood as hypothesis generating.  
 
That experienced experts did not converge more rapidly on aggregated expert opinion should not 
be interpreted as questioning the value of expertise. More experienced experts are likely to 
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contribute to funding and policy decisions in other important ways, including the identification 
of factors that need to be considered when making forecasts.[11] Our survey nevertheless 
provides a meaningful synthesis of state-of-the art expert opinion on the expected timing of 
several major breakthroughs in Parkinson’s disease research. Many patients and caregivers show 
intense interest in learning about emerging new treatments; their expectations are often buffeted 
by hyperbolic claims in the press, on the internet or from pharmaceutical companies with a 
vested interest in particular therapies. Our forecasts provide a more objective representation of 
how expert communities interpret available evidence about when major advances will occur. 
They also provide healthcare system planners with an appraisal of the level of optimism about 
the availability of new therapies, diagnostics, and research techniques in the coming decade. 
Ultimately, the approach we employed of soliciting expert forecasts, and weighting them using 
coherence, can also be of use in helping funders, like disease charities or pharmaceutical 
companies, access accurate expert judgments of where to invest their resources.  The approach of 
elicitation and aggregation is more likely to avoid many of the biases that accrue due to psycho-
social dynamics that emerge with committees[12] or other expert elicitation platforms.[13] 
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Figure 2:  Coherence weighted mean forecasts for each milestone, arranged in descending order 
of probability of nonattainment within 10 years.  Each bin contains the coherence weighted mean 
predicted probability of the milestone occurring in that bin.  
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Topic Event Full description 
Gene Therapy FDA approval 
The FDA approves a gene therapy directed at a monogenetic cause 
of PD such as LRRK2, GBA or parkin for treatment of Parkinson’s 
disease. 
Immuno-
therapy Trial results 
A rigorous phase 2 or phase 3 clinical trial testing an alpha-
synuclein based immunotherapy for Parkinson’s disease reports a 





of the Year 
Science magazine awards "Breakthrough of the Year" to a 
molecule, process, cell, or discovery that is expressly described, in 
the accompanying Science article, as implicated in Parkinson's 
disease pathogenesis or possible treatment. 
Cell Therapy* Trial initiation 
The launch of a rigorous phase 2 or phase 3 clinical trial involving 
implantation of Parkinson's patients with dopaminergic cells 
derived from pluripotent stem cells. 
Drug 
repositioning Trial results 
A rigorous phase 3 clinical trial utilizing a repositioned medication 
and aimed at slowing the progression of Parkinson's symptoms 
reports a positive outcome on a primary efficacy endpoint. 
Treatment for 
PD-MCI* Trial initiation 
Launch of a rigorous phase 3 clinical trial testing a novel, non-
cholinesterase inhibiting drug in the treatment of PD-MCI. 
Imaging* Trial initiation A selective alpha synuclein imaging agent is integrated into a rigorous Parkinson's interventional clinical trial. 
Exercise 
therapy Trial results 
A rigorous phase 2 or phase 3 clinical trial testing the effect of 
exercises, physical activity, or physical therapy on Parkinson's 
progression reports a positive outcome on a primary efficacy 
endpoint. 
Deep Brain 
Stimulation FDA approval 
FDA approval of the first closed-loop deep brain stimulation 





A rigorous phase 2 or phase 3 clinical trial in Parkinson's disease 
that specifies eligibility based on GBA mutational status 
successfully enrolls at least 80 subjects. 
Body worn 
sensors 
Clinical practice guideline 
recommendation 
An algorithm derived from a body worn sensor is accepted by the 
International Parkinson and Movement Disorder Society as a valid 
measure of Parkinson's disease symptoms. 
 
Table 1: List of milestones used in our survey.  Additional clarifying details for some of the 
milestones were listed as footnotes (see Supplementary Materials).  Milestones with asterisks 
included an additional question asking experts to forecast the probability the given trial would 
report a positive outcome on its primary endpoints. 
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Next 2 years 6.5% (10.9%) 8.0% (9.3%) 0.057 
2-6 years 18.9% (15.7%) 20.9% (14.7%) 0.45 
6-10 years 31.8% (19.2%) 29.9% (19.0%) 0.71 




Next 2 years 21.9% (24.0%) 17.0% (20.6%) 0.23 
2-6 years 31.8% (18.9%) 31.2% (17.7%) 0.77 
6-10 years 28.4% (22.8%) 31.2% (20.3%) 0.12 
Not in next 10 years 17.9% (22.1%) 20.6% (22.2%) 0.20 
 
Table 1: Means and standard deviations of the forecasts for each time bin for the two milestones 
dealing with the FDA for the North American and non-North American experts, as well as the p-
values for a two sided Komogorov-Smirnov test of equality of distributions for the two samples 
of forecasts for each time bin. 
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Treatment Category FDA Approval Prediction Mean (SD) 
Gene Therapy  43.9% (28.6%) 
Repurposed Small Molecule Therapy 46.5% (26.1%) 
Novel Small Molecule Therapy 45.4% (27.8%) 
Stem Cell Therapy 34.2% (24.6%) 
Therapy Not Falling in the Preceding Categories 37.4% (28.4%) 
 
Table 3: Mean and standard deviation of experts' predictions of the probability of an FDA 




Treatment Categories Familiarity Mean (SD) Clinical Promise Mean (SD) 
Gene Therapy 3.8 (1.9) 5.5 (2.1) 
Precision Medicine 4.3 (1.6) 6.3 (1.8) 
Alpha Synuclein 4.2 (1.8) 5.9 (2.0) 
Deep Brain Stimulation 4.9 (1.7) 6.3 (1.6) 
 
Table 4: Mean and standard deviations for expert Likert scale ratings of familiarity with 
different kinds of PD treatment.  Note that familiarity ratings were performed on a 7-point scale 
while clinical promise ratings were performed on a 9 point scale. 
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Variable Coefficient P-Value 
Intercept (Gene Therapy, Female, 
Masters or less) 
18.78 <0.001 
Immunotherapy 0.64 0.62 
Basic Science Discovery 0.86 0.51 
Cell Therapy -1.18 0.36 
Drug Repositioning -1.30 0.32 
Treatment for PD-MCI -3.63 0.005 
Imaging -3.08 0.02 
Exercise Therapy -0.42 0.75 
Deep Brain Stimulation -5.03 <0.001 
Precision Medicine Therapy -5.21 <0.001 
Body Worn Sensor -5.82 <0.001 
MD 3.70 0.02 
MD-PhD 3.14 0.05 
PhD 4.22 0.007 
Gender Male 1.79 0.007 
Gender Unspecified -1.09 0.80 
Age -0.003 0.93 
Clinical Trials -0.006 0.44 
H-index 0.004 0.79 
 
Table 5: Coefficients for the regression of deviation from the coherence weighted mean on 
demographic variables.  Coefficients are interpreted as the change in deviation associated with a 
one unit change in the associated variables. 
 
